Advertisement

Topics

Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA Pipeline Review, H1 2018 [Report Updated: 10042018] Prices from USD $3500

13:14 EDT 31 Jul 2018 | BioPortfolio Reports

Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA Pipeline Review, H1 2018


Summary


According to the recently published report 'Interleukin 2 Receptor Subunit Alpha Pipeline Review, H1 2018'; Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies.


Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA Interleukin2 receptor alpha is a protein that is encoded by the IL2RA gene. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells TREGs activity. TREGs suppress the activation and expansion of autoreactive Tcells.


The report 'Interleukin 2 Receptor Subunit Alpha Pipeline Review, H1 2018' outlays comprehensive information on the Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.


It also reviews key players involved in Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 3, 2, 3 and 1 respectively.


Report covers products from therapy areas Immunology, Oncology and Cardiovascular which include indications Melanoma, Systemic Lupus Erythematosus, Autoimmune Disorders, Blood Cancer, Diffuse Large BCell Lymphoma, Graft Versus Host Disease GVHD, Kidney Transplant Rejection, Metastatic Melanoma, Ovarian Cancer, Pulmonary Arterial Hypertension, Renal Cell Carcinoma, Solid Tumor and Stroke.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA

The report reviews Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA Pipeline Review, H1 2018 [Report Updated: 10042018] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA Pipeline Review, H1 2018 [Report Updated: 10042018] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...